Compare AMETEK, Inc. (AME) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Canopy Growth Corp — how do they compare? AMETEK, Inc. trades at $258.78 (market cap $58.76B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: AMETEK, Inc. is far larger — about 139.5× Canopy Growth Corp's market cap, and AMETEK, Inc. pays a 0.53% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| AME | CGC | |
|---|---|---|
Market Cap | $58.76B | $421.10M |
Sector | Industrials | Health |
52-Week High | $256.30 | $1.92 |
52-Week Low | $179.28 | $0.86 |
Enterprise Value | $60.30B | $378.55M |
Dividend Yield | 0.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME's stock trades at $257.9, up 1.99% today, reflecting strong momentum after recent earnings beats. The company reported record Q2 2026 results with EPS of $2.09, exceeding estimates, and raised full-year guidance. Valuation metrics like a P/E of 37.47 and P/S of 7.51 are elevated, but supported by robust profitability, including a 20.04% net income margin and 14.56% ROE. Technical indicators show a bullish trend, with the current price near resistance at $258.
The outlook remains positive, driven by consistent earnings growth and strong demand across business segments. Key risks include high valuation multiples and potential economic headwinds. With a consensus price target of $281.86 and no sell ratings from analysts, the stock offers upside potential, but investors should monitor execution against guidance and market volatility.
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
